The quarterly cash flow came in $1.4m less than forecast. That is $2.3M outflow vs a forecast of $3.7M outflow. The variance was almost all attributable to R&D, which was $1.2M less than forecast. The forecast outflow for the next quarter is $2.3M, same as this quarter. This leaves the company with enough cash until the middle of 2021 at the current rate, and assuming no inflows. So, pros and cons. The only con I could come up with was less spend on R&D which may (not likely) mean limited further exploration of 2591. From a pro perspective, there are many. Most obvious is the fact that cash from dilution is not around the corner. This also means there should be no desperation in any deals as there is no need to rush (not that there has ever seemed to be desperation, but....). I was bullish before this seemingly innocuous quarterly, but I am more so now. Onwards we march, heads held high I reckon.
NEU Price at posting:
$2.83 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)